IOPtima device shows promise for glaucoma

09/21/2007 | Israel21c

Israel-based IOPtima Ltd. has developed OT134, a carbon dioxide laser device that allows eye surgeons with less training to more easily operate on patients with glaucoma. "Our system offers better efficacy and safety advantages, as well as the risk of far fewer complications over traditional drug and surgery therapies for glaucoma," CEO Joshua Degani said.

View Full Article in:

Israel21c

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC